Human care company Elekta AB (STO:EKTAB.ST) announced on Wednesday the receipt by its Elekta Unity magnetic resonance radiation therapy (MR/RT) system of 510(k) premarket notification from the US Food and Drug Administration, clearing the technology for commercial sales and clinical use in the US.
Reportedly, Elekta Unity had received CE mark in June 2018 and has been transforming the care of cancer patients in Europe.
According to the company, with Elekta Unity, it is now feasible to develop personalised, precision radiation therapy regimens that are optimised for safety and efficacy and make radiation therapy a viable treatment option for more patients.
Also, Unity has the potential to transform how clinicians treat cancer by enabling the delivery of the radiation dose while simultaneously visualising the tumour and surrounding healthy tissue with high-quality MR images. Unity also integrates advanced tools that allow clinicians to adapt the patient's treatment to this current anatomical information within a treatment session.
Elekta offers treatment solutions and oncology informatics portfolios that are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, as well as to drive cost efficiency in clinical workflows.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data